Evidence map›Paper›PMID 29535851›Full record

ReviewJournal of extracellular vesicles2018

Glycosylation of extracellular vesicles: current knowledge, tools and clinical perspectives.

Charles Williams, Felix Royo, Oier Aizpurua-Olaizola, Raquel Pazos, Geert-Jan Boons, Niels-Christian Reichardt, Juan M Falcon-Perez

Open access · goldAbstract readReview
In one paragraph

Review in Journal of extracellular vesicles, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 1 synthesis or guideline pooled it, 246 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Charles WilliamsExosomes Laboratory. CIC bioGUNE, CIBER, Bizkaia, Spain.ORCID 0000-0001-7781-8693
Felix RoyoExosomes Laboratory. CIC bioGUNE, CIBER, Bizkaia, Spain.
Oier Aizpurua-OlaizolaExosomes Laboratory. CIC bioGUNE, CIBER, Bizkaia, Spain.ORCID 0000-0003-2321-2113
Raquel PazosGlycotechnology Laboratory, CIC BiomaGUNE, San Sebastian, Spain.
Geert-Jan BoonsDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-3111-5954
Niels-Christian ReichardtGlycotechnology Laboratory, CIC BiomaGUNE, San Sebastian, Spain.ORCID 0000-0002-9092-7023
Juan M Falcon-PerezExosomes Laboratory. CIC bioGUNE, CIBER, Bizkaia, Spain.
CIC biomaGUNE · ESUtrecht University · NLCIC bioGUNE · ESIkerbasque · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is now acknowledged that extracellular vesicles (EVs) are important effectors in a vast number of biological processes through intercellular transfer of biomolecules. Increasing research efforts in the EV field have yielded an appreciation for the potential role of glycans in EV function. Indeed, recent reports show that the presence of glycoconjugates is involved in EV biogenesis, in cellular recognition and in the efficient uptake of EVs by recipient cells. It is clear that a full understanding of EV biology will require researchers to focus also on EV glycosylation through glycomics approaches. This review outlines the major glycomics techniques that have been applied to EVs in the context of the recent findings. Beyond understanding the mechanisms by which EVs mediate their physiological functions, glycosylation also provides opportunities by which to engineer EVs for therapeutic and diagnostic purposes. Studies characterising the glycan composition of EVs have highlighted glycome changes in various disease states, thus indicating potential for EV glycans as diagnostic markers. Meanwhile, glycans have been targeted as molecular handles for affinity-based isolation in both research and clinical contexts. An overview of current strategies to exploit EV glycosylation and a discussion of the implications of recent findings for the burgeoning EV industry follows the below review of glycomics and its application to EV biology.

Indexed as

exosomesExtracellular vesiclesglycansglycoengineeringglycomicsglycosylationlectinsmicrovesicles

Identifiers

PMID29535851
PMCPMC5844028
OpenAlexW2789390897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.